Sangamo Biosciences Inc. (NASDAQ:SGMO) Q4 2018 Earnings Conference Call Transcript
Nov 08, 2018 • 05:00 pm ET
Good afternoon and welcome to the Sangamo Therapeutics Teleconference to discuss Fourth Quarter and Full Year 2018 Financial Results. This call is being recorded.
I will now pass you over to the coordinator of this event, McDavid Stilwell, Vice President of Corporate Communications and Investor Relations.
Hello, and thank you for joining us. As we begin, I'd like to point out that we'll be referencing an accompanying slide presentation. A link to the slide presentation may be found on our website, sangamo.com on the Events and Presentations page of the Investors and Media section of the site.
I'd also like to remind everyone that the projections and forward-looking statements that we'll discuss during this conference call are based upon information that we have available today. This information will likely change over time. By discussing the future performance of Sangamo with you today, we are not undertaking an obligation to provide updates in the future. Actual results may differ substantially from what we discuss today, and no one should assume at a later date that our comments from today are still valid. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are detailed in documents that the Company files with the Securities and Exchange Commission, specifically, our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. The forward-looking statements stated today are made as of this date and Sangamo undertakes no duty to update such information except as required under applicable law.
With me this afternoon on this call are several members of the Sangamo senior management team including Sandy Macrae, Chief Executive Officer; Kathy Yi, Chief Financial Officer; Stephane Boissel, Executive Vice President, Corporate Strategy; Adrian Woolfson, Executive Vice President and Head of Research and Development; and Ed Conner, Chief Medical Officer.
Again, we'll refer to a slide presentation during this call. And those slides are to be found on the Events and Presentation page of the Investors and Media section of the site.
And now I'd like to turn the call over to Sandy.
Thank you, McDavid. And good afternoon to everyone on the call. Thank you for joining us. At Sangamo, we are focused on the development of novel genomic medicines using scientific expertise we have developed for over two decades. We have five active clinical trials. And at the end of this year, we'll have a total of nine programs in our clinic.
Our pipeline of therapeutic genomic medicine candidates currently in clinical development encompass three complementary approaches: gene therapy, ex vivo genome medicine and in vivo genome medicine. We are sometimes asked why Sangamo, a company best known for genome editing, includes the gene therapy programs in its clinical development portfolio. The answer is simple: we believe that the application of a variety of mutually compatible approaches to the problem of treating genetic diseases is both necessary and appropriate. Our use of gene therapy is, in one sense, pragmatic. We have a deep knowledge of